Adriana Elizabeth Monsiváis Urenda

Advanced Search

Contact:

gci@uaslp.mx

Búsqueda Investigador

Researcher profile

Adriana Elizabeth Monsiváis Urenda

Personal Data:

Academic Degree: PhD Degree

SNI Level: II

ORBIS ID: n70534

Institutional Data:

Affiliation: Faculty of Medicine

Research Unit: Biomedicine and Health Research Center

Office address: Av. Sierra Leona 550 Lomas 2a. Sección CP. 78210 San Luis Potosí

Phone number: (+52) 4448261450

Ext.: 8534

Email: adriana.urenda@uaslp.mx

PhD Degree in Basic Biomedical Sciences PhD
Universidad Autónoma de San Luis Potosí
Master's Degree in Basic Biomedical Sciences MSc
Universidad Autónoma de San Luis Potosí
Bachelor's Degree in Medicine
Universidad Autónoma de San Luis Potosí

Personal Researchs Interest

Immunological mechanisms involved in the pathogenesis of inflammatory chronic diseases.

Research Interests of Research Group

Immunology of Autoimmune Skin Deseases
Immune system and its role in chronic inflammatory diseases

Artículo
- Altered Phenotype of Circulating Dendritic Cells and Regulatory T Cells from Patients with Acute Myocarditis. Journal of Immunology Research. 2022:-. 2022-01-01
- Differentiation of circulating monocytes into macrophages with metabolically activated phenotype regulates inflammation in dyslipidemia patients. Clinical and Experimental Immunology. 208:83-94. 2022-01-01
- Increased levels of pathogenic Th17 cells and diminished function of CD69%2bTreg lymphocytes in patients with overweight. Clinical and Experimental Immunology. 209:115-125. 2022-01-01
- Expression and immunogenicity assessment of a plant-made immunogen targeting the cytotoxic T-lymphocyte associated antigen-4: a possible approach for cancer immunotherapy. Journal of Biotechnology. 329:29-37. 2021-01-01
- Altered NK cell receptor repertoire and function of natural killer cells in patients with acute myocardial infarction: A three-month follow-up study. Immunobiology. 225:-. 2020-01-01
Capítulo de Libro
- Basic virological aspects of SARS-CoV-2. Biomedical Innovations to Combat COVID-19. 1-30. 2022-01-01